“85% of failures are us having failed the molecule, not the molecule having not delivered.”
During the Life Sciences Week in London, Adil Ali, MD, founder of Onyx News Room, caught up with Ali Pashazadeh, CEO of Treehill Partners, to find out why:
– 50% of Phase III drugs fail (and how 75% of those failures could be avoided)
– Biotech execs think in verticals, when they should be thinking horizontally
– We don’t see IPOs from British biotechs
The interview has translated into a must-watch for investors, strategy teams and founders alike – watch it HERE.